Bergwerk Dov reported option exercise involving 8,755 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $28.98 for $254k on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Interim Cheif Legal Officer
Interim Cheif Legal Officer
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$253,719.90Shares × reported price
Shares traded
8,755Ordinary Shares
Price per share
$28.98Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,698Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 6, 2026, 4:01 PM ET2-day reporting delay
Accession
0001193125-26-451804Code M · Transaction 394569
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −6.9%1w ago −6.2%1d ago −4.7%
Returns since7d +4.4%30d90d180d1y

Footnotes in full

F1: Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 4,377 having vested on March 3, 2021. F2: Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020, and 2,191 having vested on May 24, 2021.